Pranav Amin

When asked about the growth projections of the company in the next quarters, Pranav Amin, Managing Director, said it depends on how the market performs.

Alembic Pharma net profit rises 2% in Q4, expenses rise 24%

“We have closed out very good year where our facilities remain in compliance and we continue to invest for the future,” said Pranav Amin, managing director, Alembic Pharmaceuticals

Alembic Pharma Q2 net dips 58% to Rs 119.83 cr

The company had posted a net profit of Rs 288.51 crore for the corresponding period of the previous fiscal.

We are planning 6-8 new launches this fiscal yr: Alembic Pharma

Speaking to CNBC-TV18 Pranav Amin, Managing Director of Alembic Pharmaceuticals, said that good Q1 numbers were led by international business. Sales of its anti-psychotic drug Abilify was one of the reasons the company saw higher sales, he said.

EBITDA margin came off unusually high base: Alembic Pharma

In an interview with CNBC-TV18‘s Ekta Batra and Reema Tendulkar, Pranav Amin, Director & President- International Business, Alembic Pharmaceuticals, discussed the company‘s quarterly earnings.

Alembic Pharma expects API biz to grow 10% in FY15

The growth for the international generics, however, remain muted at about 9 percent due to higher base last year.

See 20% EBITDA growth in FY14: Alembic Pharma

In an interview to CNBC-TV18, Amin adds that the company, despite the drug pricing policy, will grow at 15 percent.

ANDAs will benefit FY13 and FY14 numbers: Alembic Pharma

Alembic Pharma has announced its third quarter results. Pranav Amin, director of Alembic Pharma says, the revenues have gone up 15%, YoY. He further says, the company so far has filed 41 abbreviated new drug applications (ANDAs). “Over the next couple of years, we should see quite a bit of growth coming in international generic,” he adds.